What are the main takeover defenses available to a target board, and how effective are they?
A core M&A Advisory interview question — asked in analyst and associate interviews across IB, PE, and the Big 4.
THE SHORT ANSWER
Classic (mostly US) structural defenses: a poison pill (shareholder rights plan) that massively dilutes a hostile bidder once it crosses an ownership threshold, making an unapproved acquisition prohibitively expensive — the most effective deterrent, forcing bidders to negotiate with the board; a staggered/classified board so a bidder can't replace directors in one cycle; dual-class shares concentrating voting control with insiders; and white-knight/white-squire defenses (inviting a friendly alternative buyer or stake). Tactical responses include a 'just say no' defense, value-based defenses (showing the bid undervalues the company, special dividends, buybacks), and crown-jewel or scorched-earth tactics (less common, often value-destructive). Effectiveness and legality vary hugely by jurisdiction: defenses are powerful in the US (subject to fiduciary/Revlon/Unocal scrutiny) but heavily restricted in others — the UK Takeover Code, for instance, has a board-neutrality rule that largely prohibits frustrating actions without shareholder approval, so European boards rely more on persuading shareholders the price is inadequate.
WHAT INTERVIEWERS LISTEN FOR
- ✓Poison pill (rights plan) is the strongest — forces negotiation
- ✓Staggered board, dual-class shares, white knight
- ✓Value defenses (show undervaluation, buybacks/dividends)
- ✓Availability differs: strong in US, restricted by UK board-neutrality rule
COMMON MISTAKES
- ✗Assuming pills are available everywhere
- ✗Ignoring board-neutrality rules outside the US
- ✗Recommending value-destructive scorched-earth tactics
Reading isn't the same as answering under pressure.
Interviewers don't hand you the model answer — you deliver yours on a clock. Practice this and 1,000+ questions with AI feedback on every answer.
RELATED QUESTIONS
- A client wants to buy at 12x EBITDA for a business with 5% growth and 15% margins. What's your advice?
- How do you value synergies?
- When would you use an earn-out versus an escrow?
- What's the most important clause in an SPA?
- What are the most common reasons why M&A deals fail to create value, and how would you advise a client to mitigate these risks?
- How do you value cost synergies in an M&A model, and what are common pitfalls?